15.04.2011Conatus CTS-1027

Conatus Pharmaceuticals Inc. announces interim results from a clinical trial with CTS-1027

Press Release
16.02.2011Versartis Completes $21 Million Series B Financing

Completion of Versartis Series B Financing

Press Release
04.02.2011Cellnovo secures £30 million in Series B financing to advance new mobile diabetes management system

Press Release
24.11.2010Final close of Advent Life Sciences

Advent Venture Partners today announced the final close of a $120M (£75M) venture capital fund, to be called Advent Life Sciences

Press Release
04.11.2010Algeta wins Scrip Award for Biotechnology Company of the Year

Scrip's Biotech Company of the Year award seeks to acknowledge the vital importance to the industry of biotechnology’s cutting-edge science and entrepreneurial spirit.  This year, from a strong field, the judges chose Algeta as the winner.

In The News
02.11.2010Avila Presents New Data on its Novel, Orally-Available Targeted Covalent Drug, AVL-192

Avila Therapeutics™, Inc., a biotechnology company developing novel targeted covalent drugs, presented results today of preclinical studies that demonstrate its orally-available targeted covalent drug candidate, AVL-192, achieves superior potency against drug-resistant mutations of the Hepatitis C Virus (HCV).

Press Release
26.10.2010Infinity announces that Purdue Pharmaceutical Products L.P. and Mundipharma International Corporation Ltd. Exercise Rights to Develop and Commercialize Infinity's FAAH Pain Program Worldwide

Press Release
12.10.2009New phase II data presented at ECCO 15 and 34th ESMO Congress reinforces exciting potential of Algeta's Alpharadin as a new treatment for bone metastases in cancer patients

Press Release
10.10.2010Infinity Announces Promising Phase 1 Data of IPI-926 in Patients With Advanced or Metastatic Solid Tumors

Press Release
06.10.2010Pathwork Diagnostics Completes $30M Series C Round

Capital to Accelerate Commercialization and Market Share for FDA-cleared Tissue of Origin Test

Press Release